Women outlive men in every country for which reliable data exist. The gap varies, typically ranging from about three to seven years of life expectancy in high-income countries, and it has narrowed and widened over time in response to changes in smoking rates, occupational exposures, and cardiovascular treatments. But women also live more of their extra years with disability, and several important aspects of aging biology and clinical care differ by sex in ways that longevity discussions often overlook.
This is not a story of one sex aging better than the other. It is a story of different trajectories, different vulnerabilities, and, in many domains, evidence bases that were built primarily on male participants and then extrapolated.
The lifespan gap and its uneven quality
The female longevity advantage appears across mammalian species to some degree and is influenced by both biological and social factors. Contributors that researchers have implicated include:
- Sex chromosome effects, including the protective potential of a second X chromosome
- Estrogen exposure during reproductive years, which is associated with more favorable lipid profiles and vascular function
- Behavioral differences, including historically lower rates of smoking, heavy drinking, and hazardous occupations
- Immune system differences, with women generally mounting stronger immune responses, at the cost of higher autoimmune disease risk
But extra years are not automatically good years. Women, on average, spend more of their later life with functional limitations, higher rates of osteoporosis and osteoarthritis, and higher rates of dementia. The gap between life expectancy and healthspan tends to be larger for women.
Cardiovascular disease presents differently
Cardiovascular disease is the leading cause of death for both sexes globally, but its timing and presentation differ meaningfully:
- Women's first cardiovascular events occur, on average, about a decade later than men's
- Women are more likely to present with atypical symptoms during acute coronary syndromes and have historically been under-diagnosed and under-treated
- Women's coronary disease more often involves microvascular dysfunction that is less well captured by standard angiography
The combination of later onset, atypical presentation, and historical underrepresentation in trials has led to real gaps in care that professional societies have been working to close.
Menopause as a cardiometabolic transition
The menopausal transition is more than a reproductive event. The loss of estrogen is associated with:
- Rapid loss of bone mineral density in the years surrounding menopause
- Shifts in body composition toward greater visceral adiposity
- Adverse changes in lipids, insulin sensitivity, and vascular reactivity
- Sleep disruption, which itself has metabolic and cardiovascular consequences
Hormone therapy remains one of the more nuanced topics in women's health. The Women's Health Initiative results in the early 2000s led to sharp declines in use, but subsequent reanalyses have refined the picture: for many women starting therapy near the onset of menopause and without contraindications, hormone therapy appears to have a more favorable risk-benefit profile than the initial headlines suggested, though it is not a longevity intervention per se.
Where men's risks concentrate
Men face higher rates of premature cardiovascular disease, higher rates of death from injury and suicide, and higher rates of certain cancers. Testosterone declines gradually with age rather than dropping sharply. Muscle mass tends to be higher at baseline but declines meaningfully with sedentary aging.
Men are also less likely, on average, to engage with preventive care, which contributes to later diagnosis and worse outcomes across several conditions.
Sex-specific care is not about different values; it is about the same value being pursued through different biology and different risks.
Implications for a longevity plan
Some practical differences that follow from the evidence:
- Bone health screening matters earlier and more aggressively in postmenopausal women
- Cardiovascular risk assessment in women should include pregnancy-related conditions such as preeclampsia and gestational diabetes, which independently predict later risk
- Strength training matters especially for postmenopausal women, given accelerated bone and muscle loss
- Mental health and suicide risk deserve particular attention in men, especially at life transitions
- Cancer screening schedules appropriately differ by sex and organ
The bottom line
Women live longer, but not necessarily healthier, and much of medical evidence has been built on data that underrepresented them. Longevity strategies benefit from taking seriously the sex-specific trajectories of cardiovascular disease, hormonal transitions, musculoskeletal aging, and mental health, rather than assuming a single template applies to everyone.